Hormone replacement in patients after age 60

Testosterone isn't just a "vitality hormone" — it plays a direct role in maintaining muscle mass, bone density, mood, and sexual function. As men age, especially after 60, levels tend to decline progressively. That raises an increasingly common question in clinical practice: when does testosterone replacement actually help — and for whom?

What the age-related decline in testosterone actually means

An important point, reinforced by the Endocrine Society's guideline (the leading international endocrinology society): terms like "age-related hypogonadism" tend to blur the line between a treatable condition and normal aging. The recommendation is clear — a diagnosis of hypogonadism requires consistent symptoms (such as decreased libido, erectile dysfunction, loss of muscle strength, increased body fat, mood changes) combined with consistently low testosterone levels, confirmed by more than one fasting morning measurement.15 In other words: age alone isn't a diagnosis, and a low number by itself (without symptoms) isn't enough either.

The documented benefits from rigorous studies

When replacement is properly indicated, the evidence of benefit is real and comes from robust trials:

• The Testosterone Trials (TTrials), a set of randomized controlled trials involving nearly 800 men aged 65 and older with low testosterone and symptoms, showed statistically significant gains in lean mass and lower-body strength with replacement, along with benefits for sexual function and mood symptoms.16
• In the bone substudy of the TTrials, trabecular spine bone mineral density increased by about 6.8% over 12 months — a relevant finding, since bone loss and fractures are serious complications of aging.
• This connects directly to the theme of preserving muscle mass after 40: adequate testosterone is one of the hormonal factors that support the body's ability to maintain and build muscle, especially when combined with strength training.

What cardiovascular safety data showed — and the points of caution

For many years, testosterone replacement was surrounded by uncertainty about cardiovascular risk. The TRAVERSE trial, the largest and most rigorous study ever conducted on this topic (over 5,000 men with hypogonadism and preexisting cardiovascular risk), provided an important answer: testosterone replacement did not increase the risk of major cardiac events (heart attack, stroke, cardiovascular death) compared with placebo.17

That doesn't mean "no risks." The same study found a higher incidence of atrial fibrillation, venous thromboembolism, and fractures in the treated group — which is why replacement requires ongoing medical follow-up, not self-directed use.

What about prostate cancer?

This has historically been the biggest concern surrounding testosterone. A meta-analysis pooling 22 randomized controlled trials (over 2,300 patients) found no increased risk of prostate cancer development or progression with replacement in the short term — but the authors themselves note that longer-term follow-up data are still needed.18 That's exactly why prostate monitoring (clinical exam, PSA) is part of follow-up for any man on hormone replacement — it isn't an optional step.

Why this matters, in a balanced way

Putting this evidence together: for the right patient — someone with real symptoms and consistently low, properly investigated testosterone — hormone replacement, when properly indicated and monitored, can offer genuine benefits for muscle mass, bone density, mood, and quality of life, with a cardiovascular safety profile that is now better established than it was thought to be a few years ago. This is particularly relevant after age 60, when sarcopenia, bone loss, and hormonal decline tend to overlap.

At the same time, this isn't a conversation about "replacing as routine" or treating a low number in isolation. It's about correct diagnosis, real indication, and ongoing medical follow-up — exactly the model supported by the most current international guidelines.

References

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. academic.oup.com
2. Snyder PJ, Bhasin S, Cunningham GR, et al., for the Testosterone Trials Investigators. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-624. nejm.org
3. Lincoff AM, Bhasin S, Flevaris P, et al., for the TRAVERSE Study Investigators. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023. nejm.org
4. Cui Y, Zong H, Yan H, Zhang Y. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2014;17(2):132-143. nature.com

This content is educational, based on international medical literature, and does not replace individual medical evaluation. Testosterone replacement requires confirmed lab diagnosis, symptom assessment, and ongoing follow-up — it should never be started on one's own.